Active Ingredient History
Endostatin is a naturally occurring, 20-kDa C-terminal fragment derived from type XVIII collagen. It is reported to serve as an anti-angiogenic agent, similar to angiostatin and thrombospondin. Wikipedia
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Adenocarcinoma of Lung (Phase 4)
Angiogenesis Modulating Agents (Phase 3)
Ascites (Phase 2)
Brain Neoplasms (Phase 2)
Breast Neoplasms (Phase 3)
Carcinoma, Hepatocellular (Phase 2)
Carcinoma, Non-Small-Cell Lung (Phase 4)
Colorectal Neoplasms (Phase 3)
Endostatins (Phase 2)
Esophageal Diseases (Phase 2)
Esophageal Neoplasms (Phase 4)
Esophageal Squamous Cell Carcinoma (Phase 2)
Glioblastoma (Phase 2)
Glioma (Phase 2)
Head and Neck Neoplasms (Phase 3)
Lung Neoplasms (Phase 4)
Lymphoma, T-Cell (Phase 2)
Lymphoma, T-Cell, Peripheral (Phase 2)
Magnetic Resonance Imaging (Phase 2/Phase 3)
Melanoma (Phase 2)
Nasopharyngeal Carcinoma (Phase 3)
Nasopharyngeal Neoplasms (Phase 3)
Neoplasm Metastasis (Phase 4)
Neoplasms (Phase 2)
Neuroblastoma (Phase 2)
Neurofibromatosis 2 (Phase 2)
Neuroma, Acoustic (Phase 2)
Optic Nerve Glioma (Phase 2)
Osteosarcoma (Phase 2)
Pancreatic Neoplasms (Phase 2)
Pharmacokinetics (Phase 1)
Pleural Effusion, Malignant (Phase 3)
Quality of Life (Phase 2/Phase 3)
Radiation Pneumonitis (Phase 2)
Sarcoma (Phase 2)
Small Cell Lung Carcinoma (Phase 2)
Soft Tissue Injuries (Phase 2)
Stomach Neoplasms (Phase 3)
Uterine Cervical Neoplasms (Phase 3)
Trial | Phase | Start Date | Organizations | Indications |
---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue